Table 2 The diagnostic efficiency of CEA, CA72-4, CA19-9, and TrxR in discriminating GC patients with various pathological TNM stages from healthy controls.
From: Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer
Tumor markers | GC patients before clinical intervention | ||||||
|---|---|---|---|---|---|---|---|
AUC (95%CI) | SEN% | SPE% | PPV% | NPV% | PLR | NLR | |
GCs stage I vs. healthy controls | |||||||
TrxR | 0.948 (0.900–0.995) | 80.00 | 97.69 | 97.20 | 83.01 | 34.67 | 4.88 |
CEA | 0.518 (0.363–0.673) | 32.00 | 93.85 | 83.87 | 57.98 | 5.20 | 1.38 |
CA72-4 | 0.613 (0.491–0.735) | 28.00 | 93.85 | 81.98 | 56.59 | 4.55 | 1.30 |
CA19-9 | 0.493 (0.375–0.612) | 84.00 | 26.15 | 53.22 | 62.04 | 1.14 | 1.63 |
GCs stage II vs. healthy controls | |||||||
TrxR | 0.955 (0.914–0.997) | 84.62 | 97.69 | 97.35 | 86.39 | 36.67 | 6.35 |
CEA | 0.653 (0.530–0.775) | 48.72 | 99.23 | 98.45 | 65.93 | 63.33 | 1.94 |
CA72-4 | 0.605 (0.508–0.703) | 79.49 | 43.08 | 58.27 | 67.74 | 1.40 | 2.10 |
CA19-9 | 0.593 (0.494–0.693) | 89.74 | 34.62 | 57.85 | 77.14 | 1.37 | 3.38 |
GCs stage III vs. healthy controls | |||||||
TrxR | 0.971 (0.946–0.997) | 89.13 | 96.15 | 95.86 | 89.94 | 23.17 | 8.85 |
CEA | 0.923 (0.862–0.984) | 84.78 | 100.00 | 100.00 | 86.79 | − | 6.57 |
CA72–4 | 0.816 (0.740–0.891) | 63.04 | 93.85 | 91.11 | 71.15 | 10.24 | 2.54 |
CA19-9 | 0.721 (0.633–0.810) | 41.30 | 100.00 | 100.00 | 63.01 | − | 1.70 |
GCs stage IV vs. healthy controls | |||||||
TrxR | 0.974 (0.942–1.000) | 90.48 | 97.69 | 97.51 | 91.12 | 39.21 | 10.26 |
CEA | 0.912 (0.834–0.990) | 76.19 | 100.00 | 100.00 | 80.77 | − | 4.20 |
CA72-4 | 0.842 (0.741–0.944) | 66.67 | 93.85 | 91.55 | 73.79 | 10.83 | 2.82 |
CA19-9 | 0.814 (0.711–0.916) | 53.68 | 100.00 | 100.00 | 67.74 | − | 2.10 |
